1145P Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: Analysis of a prospective German MCC registry (MCC TRIM)
Jürgen C. Becker(Düsseldorf University Hospital), S. Ugurel-Becker(Ruhrlandklinik), Patrice Verpillat(Centre National de la Recherche Scientifique), Claudia Pfoehler(MSH Medical School Hamburg – University of Applied Sciences and Medical University), Dirk Schadendorf(National Center for Tumor Diseases), Emmanuelle Boutmy(Merck KGaA, Darmstadt (Germany)), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Stephan Grabbe(Goethe University Frankfurt), Fabian Ziller(Vivantes Klinikum), U. Leiter-Stoppke(University of Tübingen), Martin Sachse(Institut Pasteur), Margarita Shlaen, Saeed Mahmoudpour, Lisa Zimmer(The University of Sydney), Changbo Fu(Fudan University), Anthony F. Milano, Rudolf Herbst(Helios Klinikum Erfurt), Steven J. Hoff(Merck KGaA, Darmstadt (Germany)), Christoffer Gebhardt(Universität Hamburg)
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k